. Clinicopathological characteristics of patient cohorts I (CSS or OS) Table S2 . Clinicopathological characteristics of patient cohorts II (DFS) Table S3 . PCR primers used in this study Table S4 . Genes with strongest survival associations by SSAT analysis. A semi-supervised survival tool (SSAT), an R (Bioconductor) based script, was used in silico to identify genes whose expression correlated with overall survival in colon cancer. SSAT identified 400 and 269 such genes in two datasets, GSE17536 and GSE17537, respectively, of which 64 were in common to both datasets. Twenty genes, which were most significantly associated with survival based on a weighted rank score are shown in Table S4 . Table S5 . MVA-1. A multivariate cox proportional hazard analysis (backward Wald) identified 3 genes (ULBP2, SEMA5A and PCDH7) that remained in the equation, in addition to stage.
These 3 genes and stage were then used for a second MVA (backward Wald), this time using GSE17537 data. ULBP2 and SEMA5A were the only two genes whose upregulation were associated with worse and better overall survival, respectively, independent of stage in this analysis. Downregulation of ULBP2 and upregulation of SEMA5A was related to better overall survival. Table S6 . Univariate cox regression analyses of ULBP2 and SEMA5A gene expression with CSS Table S7 . Stage 2&3 restricted MVA of CSS with clinicopathological parameters and SU-GIB in GSE17536 Table S8 . Cox regression analysis with GSE39582 MSS samples only. Survival times are in months. SU-GIB signature cut-off values for ULBP2 and SEMA5A were the median values which were identical to the cut-off with the smallest log rank p value within the 25-75 th % interquartile range for both genes. Figure S1 A B C Figure S2 A B C D Figure S3 A B C D Figure S4 ULBP2 SEMA5A Figure S5 A B C D Figure S6 A B C Figure 
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